Last updated on August 2018

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma

Brief description of study

The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.

Clinical Study Identifier: NCT02676869

Contact Investigators or Research Sites near you

Start Over

Immutep Australia Pty Ltd

Alfred Hospital
Melbourne, Australia